CIPLA LTD (500087) — Latest Corporate Announcements
₹1,324
+₹12.70 (+0.97%)
Market Cap
₹1,06,962.07 Cr
P/E Ratio
32.00
52W Range
₹1165.7 – ₹1673
Board Meeting Intimations
📅 Scheduled Board Meeting & Agenda
Meeting Date: 27-Oct-2026
Agenda / Purpose: Financial Results
Timeline: In 14 days
Corporate Actions & Regulatory Filings
Board Meeting Intimation - Results
Cipla limited has informed the Exchange about Board Meeting to be held on 27th October, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half-year ended 30th September, 2026.
Board Meeting Intimation for The Quarter And Half Year Ended 30Th September, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Change in Management
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Announcement under Regulation 30 (LODR)-Restructuring
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
USFDA Inspection At Company'S Manufacturing Facility In Pithampur, India
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Sep-2026 (Q2 FY27) | 27-Oct-2026 | Scheduled Upcoming | Cipla limited has informed the Exchange about Board Meeting to be held on 27th October, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half-year ended 30th September, 2026. |
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 23 Jul 2026 | Declared |
Financial Results For Quarter Ended 30Th June, 2026
📄 View Quarter Ended 30-Jun-2026 (Q1 FY27) Results PDF ↗ |
| Year Ended 31-Mar-2026 (Q4 FY26) | 13-May-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 23-Jan-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 30-Oct-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025 |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 25-Jul-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 13-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 28-Jan-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 29-Oct-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 26-Jul-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 10-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 25-Jan-2024 | Declared | CIPLA : 22-Jan-2024 : The Company has informed the Exchange that a Board meeting to be held on January 25, 2024 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on January 22, 2024, To consider and approve the financial results for the period ended December 31, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about CIPLA LTD BSE Disclosures
What is the latest BSE announcement by CIPLA LTD?
The latest BSE disclosure by CIPLA LTD (CIPLA), filed on 27 Oct 2026, is: "Board Meeting Intimation - Results". Bsenexus tracks every official filing for CIPLA LTD with AI-powered summaries on its announcements feed.
When is CIPLA LTD's next board meeting?
CIPLA LTD has a board meeting scheduled for 27-Oct-2026 (in 14 days) to consider: Financial Results.
When does CIPLA LTD declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. CIPLA LTD's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.